about   CII home   shop   checkout

CLIA Validation of Digital Cell Sorting Technology and its Ability to Overcome Limitations with Current Oncological Techniques






March 2, 2017 | 11 am to 12 pm EST

 

Sponsored by
Silicon Biosystems logo

Preview:  

 

Webinar Description:

Current enrichment techniques used on samples from mixed cell populations make CNV determinations challenging and misleading; this is because template limitation and sample heterogeneity limit the sensitivity and specificity of Next Generation Sequencing, especially when applied to FFPE or CTC samples. DEPArray can resolve this heterogeneity issue by delivering 100% pure cells which can then be subsequently profiled using the Ampli1 Low Pass kit to achieve more precise characterization and investigation of genomic complexity.

Learning Objectives:

  • Sorting 100% pure cells prior to NGS analysis is a fundamental step in obtaining reliable results
  • Demonstrate the utility of the DEPArray in a CLIA workflow
  • Study of Her2 amplification by FISH, using enriched whole cells
  • Ampli1 Low Pass CNV allows accurate characterization of copy number alteration of tumor cells

Speaker Information:

Mathew Moore, PhD.

Principal

ResearchDx

Mathew Moore is Principal and Co-Founder of ResearchDx. Dr. Moore is a seasoned diagnostics industry expert, technology advocate, and regulatory specialist. Previously he has held positions at industry leading firms including Vice President of Research and Development of Neogenomics, Inc., Vice President of Research and Development for CombiMatrix Molecular Diagnostics, Inc., Senior Scientist with US Labs and as Director of product development at Response Genetics. Dr. Moore received his Bachelors of Science degree in Biotechnology, graduating with honors. He received his Ph.D. in Biotechnology from the University of New South Wales in Sydney, Australia.

Nicolo’ Manaresi, PhD

Chief Scientific Officer

Menarini Silicon Biosystems

Nicolò Manaresi was a co-founder of Menarini Silicon Biosystems and served as its president and CEO through the early stages of the company. Prior to founding Silicon Biosystems, Dr. Manaresi was a research fellow at the University of Bologna and a long-time consultant to STMicroelectronics in the field of innovative sensors based on Microelectronic technologies. He received a Degree and Ph.D. in Electrical Engineering and Computer Sciences from the University of Bologna, Italy, in 1993 and 1999, respectively. In 1996 he spent one year as a Research assistant the Swiss Federal Institute of Technology, Zurich, Switzerland. He is co-author of more than 40 scientific papers, one of which - “A CMOS Chip for Individual Cell Manipulation and Detection” - received the IEEE 2003 International Solid Circuit Conference Jan Van Vessem Award for outstanding European papers. He is a co-inventor behind more than 30 European and US Patents.

Moderator Information:

Farideh Bischoff, PhD

Chief Clinical Development Officer, North America

Menarini Silicon Biosystems

Dr. Bischoff received her Ph.D. in Cancer Biology from University of Texas Graduated School for Biomedical Sciences (Houston, TX) followed by postdoctoral training at M.D. Anderson Cancer Center. She completed the human molecular genetics and cytogenetic fellowship program prior to joining as fulltime faculty member in the Department of Obstetrics and Gynecology at Baylor College of Medicine. She is an expert in clinical and molecular human cytogenetics and is well known in the fields of rare fetal and tumor cell recovery from peripheral blood for non-invasive molecular diagnosis. She has published extensively and demonstrated expertise in clinical study designs and commercial assay development within the fields of prenatal, oncology, infertility and preimplantation genetic diagnosis. She is currently Chief Clinical Development Officer, North America at Menarini Silicon Biosystems, Inc.



Download Webinar